Previous 10 | Next 10 |
Gainers: Seritage Growth Properties ( SRG ) +72% . Aditxt ( ADTX ) +70% . Humanigen ( HGEN ) +35% . Clovis Oncology ( CLVS ) +30% . MyMD Pharmaceuticals ( MYMD ) +27% . Oramed Pharmaceuticals ( ORMP ) +26% . Kura ...
iRhythm Technologies ( NASDAQ: IRTC ), a maker of electrocardiogram (ECG) monitoring products, added ~11% in the pre-market Friday after the company issued its comments on the Medicare reimbursement rates proposed for 2023. The Centers for Medicare and Medicaid Services ...
Shares of ophthalmic medical device concern Sight Sciences, Inc. have fallen 55% from their IPO pricing and 70% from their all-time high as the market shuns high-growth, profitless stocks. Owing to this decline, the company now trades at 4x FY22E sales net of net cash, even though tha...
Suppression of diurnal, or daily, fluctuations in IOP, is a significant and independent risk factor for the progression of glaucoma These 12-month outcomes were also confirmed by results from a subset of the study, assessing the Hispanic patient population MENLO PARK...
MENLO PARK, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced plans to participate in the upcoming Piper Sandler V...
The shares of Humacyte (NASDAQ:HUMA) are trading sharply lower on Monday after Piper Sandler downgraded the clinical-stage biotech to Underweight from Overweight expecting weakness in the near-term and citing attractiveness in the commercial-stage companies. The analysts led by Matt O'Brien c...
The following slide deck was published by Sight Sciences, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Sight Sciences, Inc. 2022 Q1 - Results - Earnings Call Presentation
Sight Sciences, Inc (SGHT) Q1 2022 Results Conference Call May 10, 2022 04:30 PM ET Company Participants Philip Taylor - Investor Relations Paul Badawi - Co-Founder and Chief Executive Officer Jesse Selnick - Chief Financial Officer Shawn O'Neil - Chief Commercial Officer Conference Call Part...
Image source: The Motley Fool. Sight Sciences, Inc. (NASDAQ: SGHT) Q1 2022 Earnings Call May 10, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Sight Sciences, Inc. (SGHT) Q1 2022 Earnings Call Transcript
Sight Sciences press release (NASDAQ:SGHT): Q1 GAAP EPS of -$0.49 misses by $0.03. Revenue of $14.88M (+72.2% Y/Y) beats by $1.29M. For further details see: Sight Sciences GAAP EPS of -$0.49 misses by $0.03, revenue of $14.88M beats by $1.29M
News, Short Squeeze, Breakout and More Instantly...
2024-06-17 00:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
MENLO PARK, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of ...
MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform car...